Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
22 Agosto 2023 - 3:00PM
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company
advancing an oral therapeutic candidate for moderate Pediatric
Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials,
announced today that an independent, key opinion leader (KOL) panel
of five pediatric endocrinologists will participate in a webinar
for discussion of PGHD, the current injectable therapeutic
landscape, and the potential for an oral treatment option for this
indication. Details are as follows:
PGHD, the Injectable Therapeutic
Landscape, and Opportunity for an Oral Treatment
Option
Virtual KOL Webinar Tuesday, September 5,
2023, 11:00 AM – 12:30 PM EDT
To register for the virtual KOL Event, please
click through the link HERE
The event will feature the following renown
thought leaders in the field of pediatric endocrinology:
- Amrit Bhangoo, MD, Section Chair and Director
of Research of the Division of Pediatric Endocrinology at the
Children’s Hospital of Orange County (CHOC) and Associate Professor
of Pediatrics at the University of California, Irvine.
- Alejandro Diaz, MD, Chief of the Division of
Pediatric Endocrinology at Niclaus Children's Pediatric Specialists
in Miami, FL.
- Erica A. Eugster, MD, Professor of Pediatrics
and Division Chief in Pediatric Endocrinology/Diabetology and
Co-Director of the Pediatric Endocrine Fellowship Program at the
Indiana University School of Medicine.
- Madhusmita "Madhu" Misra, MD, MPH, Chief of
Pediatric Endocrinology at Massachusetts General Hospital,
Physician Investigator (Cl) of Neuroendocrine at Mass General
Research Institute, Fritz Bradley Talbot and Nathan Bill Talbot
Professor of Pediatrics at Harvard Medical School, and Pediatrician
in the Pediatric Endocrinology Program and Diabetes Center at
Massachusetts General Hospital.
- Kent Reifschneider MD, Associate Professor of
Pediatrics in the Division of Endocrinology and Children’s
Specialty Group at the Children's Hospital of The King's Daughters
(CHKD), Norfolk, VA.
The moderated panel discussion will be followed
by a live question and answer session.
About PGHD and the Therapeutic
Landscape
PGHD is the consequence of inadequate secretion
of growth hormone from the pituitary gland in children resulting in
low growth hormone (GH) in the body, insufficient production of
downstream signaling molecules required for growth, and the
subsequent lack of growth. The prevailing standard of care for PGHD
consists of a daily injection of exogenous GH administered for
approximately 7 years on average. Several once-weekly injectable GH
therapies have recently been approved in the US and internationally
to treat PGHD. LUM-201, also known as ibutamoren, is an orally
administered investigational small molecule that promotes the
secretion of GH from the pituitary gland and represents an
opportunity for appropriately selected patients to avoid the daily
or weekly injections involved with current or forthcoming
therapies. LUM-201 has been observed to increase the amplitude of
endogenous pulsatile GH secretion, which mimics the natural pattern
of GH secretion.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of therapeutics for rare diseases. The Company
was founded and is led by a management team with longstanding
experience in rare disease drug development. Lumos Pharma’s lead
therapeutic candidate, LUM-201, is a novel, oral growth hormone
(GH) secretagogue, seeking to transform the $4.5B global GH market
from injectable to oral therapy. LUM-201 is currently being
evaluated in multiple Phase 2 clinical studies in Pediatric Growth
Hormone Deficiency (PGHD) and has received Orphan Drug Designation
in both the US and EU. For more information, please visit
https://lumos-pharma.com/.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Grafico Azioni Lumos Pharma (NASDAQ:LUMO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Lumos Pharma (NASDAQ:LUMO)
Storico
Da Giu 2023 a Giu 2024